Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
28 juin 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
20 juin 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
10 avr. 2024 16h30 HE
|
Cellectis Inc.
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
16 mai 2022 08h15 HE
|
Cellectis Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
28 avr. 2022 08h00 HE
|
Cellectis Inc.
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cellsPreclinical data shows proof-of-principle that UCART123 cells have...
Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March
08 mars 2021 10h24 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric...
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing
21 juil. 2020 16h30 HE
|
Cellectis Inc.
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...